A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma Journal Article

Local Library Link: Find It @ Loyola

Authors: Papadopoulos, K. P.; Lopez-Jimenez, J.; Smith, S. E.; Steinberg, J.; Keating, A.; Sasse, C.; Jie, F.; Thyss, A.
Article Title: A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma
Abstract: This phase II study evaluated YM155, a novel small-molecule survivin suppressant, in combination with rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma (NHL) who failed or were not candidates for autologous stem cell transplant (ASCT). During 14-day cycles, 41 patients received YM155 (5mg/m2/d) by continuous intravenous (IV) infusion for 168 hours (day 1-7), and rituximab (375mg/m2) IV on days 1 and 8 during cycles 1-4 and repeated for 4 cycles every 10 cycles. Forty patients (97.6%) had prior rituximab and 15 patients (36.6%) prior ASCT. Most frequent grade 3-4 adverse events were neutropenia (19.5%) and thrombocytopenia (12.2%). In the per-protocol set (n = 34), objective response rate was 50% and median progression-free survival 17.9 months. Median overall survival was not reached at study termination (median follow-up, 23 months). YM155 in combination with rituximab was tolerable with encouraging antitumor activity and durable responses in relapsed aggressive B-cell NHL patients.
Journal Title: Leukemia lymphoma
ISSN: 1029-2403; 1026-8022
Publisher: Unknown  
Date Published: 2016
Start Page: 1
End Page: 8
Language: ENG
DOI/URL:

10.3109/10428194.2015.1113275
Notes: LR: 20160210; JID: 9007422; OTO: NOTNLM; aheadofprint; SO: Leuk Lymphoma. 2016 Feb 9:1-8.